Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23230146 | 1.00 | FOLH1 (0.51) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL30602795 | 1.00 | FOLH1 (0.51) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL30428059 | 1.00 | FOLH1 (0.51) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL30300584 | 1.00 | FOLH1 (0.51) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL23230145 | 0.98 | FOLH1 (0.50) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL29563714 | 0.94 | FOLH1 (0.57) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL1711242 | 0.94 | FOLH1 (0.57) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL29368554 | 0.94 | FOLH1 (0.57) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL29511099 | 0.94 | FOLH1 (0.57) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL1711244 | 0.94 | FOLH1 (0.57) | FOLH1NOD1CPB2SLC6A5GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | claimed |
| CN-111944037-B | Synthetic method of somalupeptide | 深圳市健元医药科技有限公司 | 2023-06-13 | — | — | CN | claimed |
| CN-110845600-B | Method for preparing liraglutide | 鲁南制药集团股份有限公司 | 2022-12-27 | — | — | CN | claimed |
| EP-3320923-B1 | FLUORESCENT IMAGING AGENTS | VISEN MEDICAL INC (US) | 2022-04-06 | — | — | EP | claimed |
| US-12576136-B2 | Insulin derivative | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20250340610-A1 | ACYLATED INSULIN | GAN & LEE PHARMACEUTICALS CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| EP-4602064-A1 | METHOD OF MANUFACTURING A PEPTIDE WITH A LYSINE DERIVATIVE | Bachem Holding AG (CH) | 2025-08-20 | — | — | EP | disclosed |
| US-20250228919-A1 | Insulin Derivative | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-07-17 | — | — | US | disclosed |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | disclosed |
| WO-2025078040-A1 | LYSINE SALT AND METHOD OF MANUFACTURING A LYSINE DERIVATIVE | BACHEM HOLDING AG (CH) | 2025-04-17 | — | — | WO | disclosed |
| US-20250101063-A1 | POLYPEPTIDE COMPOUND AND USE THEREOF IN TREATMENT OF ENTERITIS | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-03-27 | — | — | US | disclosed |
| CN-119529057-A | Long acting GLP-1 compounds | 甘李药业股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-114901681-A | Insulin derivatives | 甘李药业股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114901683-A | Insulin derivatives | 甘李药业股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114901680-A | Long-acting GLP-1 compounds | 甘李药业股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114901682-A | Insulin derivatives | 甘李药业股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | disclosed |
| EP-3320923-B1 | FLUORESCENT IMAGING AGENTS | VISEN MEDICAL INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
| EP-3941485-A1 | ANTIGEN BINDING PROTEINS | Bio-Rad ABD Serotec GmbH (DE) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576136-B2 | Insulin derivative | GLP1R, IAPP, INSR | FOLH1 991/4885NOD1 1911/4885CPB2 4051/4885 |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | FOLH1 591/4885NOD1 1371/4885CPB2 471/4885 |
| US-20250340610-A1 | ACYLATED INSULIN | IAPP, GLP1R, GPR119 | FOLH1 1690/4885NOD1 1617/4885CPB2 3504/4885 |
| US-20250228919-A1 | Insulin Derivative | IAPP, GLP1R, INSR | FOLH1 3068/4885NOD1 909/4885CPB2 4435/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | FOLH1 591/4885NOD1 1371/4885CPB2 471/4885 |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | FOLH1 97/4885NOD1 329/4885CPB2 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.